Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics BRCA Test to be Reimbursed in Japan

NEW YORK – Myriad Genetics' BRACAnalysis Diagnostic System will be reimbursed in Japan as a test to identify whether individuals with hereditary breast and ovarian cancer syndrome have BRCA1/2 mutations.

Japan's Ministry of Health, Labor and Welfare (MHLW) granted regulatory approval for the diagnostic in November of last year for this indication. In February 2019, the MHLW approved the test as a companion diagnostic for the PARP inhibitor olaparib (AstraZeneca's Lynparza) in ovarian cancer, and in March 2018, it approved it as a companion diagnostic for the same drug in metastatic inoperable or recurrent breast cancer. 

The most recent reimbursement decision means the test will be covered when physicians order it for patients who meet the following criteria from the Japanese Organization of Hereditary Breast and Ovarian Cancer: their family members have BRCA1/2 mutations; they have certain personal or family history of breast cancer, ovarian cancer, or male breast cancer; or somatic testing reveals they may have  BRCA1/2 mutation and they are eligible for a PARP inhibitor.

Myriad estimates there are more than 25,000 people who meet this testing criteria in Japan, where it has partnered with SRL, a subsidiary of Miraca Group, to commercialize BRACAnalysis.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.